Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2891807 | 0.80 | ALDH1A1 (0.43) | TOP2AMAPK1ALDH1A1LMNAMAPT | |
| SCHEMBL9827267 | 0.78 | CHRM1 (0.48) | MAPK1ATMALDH1A1LMNAPKM | |
| SCHEMBL9827647 | 0.77 | KMT2A (0.35) | MAPK1ATMALDH1A1LMNAPKM | |
| SCHEMBL9828886 | 0.72 | KMT2A (0.45) | ATMALDH1A1PKMMAPTCYP2C19 | |
| SCHEMBL30990338 | 0.71 | ALDH1A1 (0.40) | ALDH1A1LMNAMAPTKMT2AKDM4E | |
| SCHEMBL10735210 | 0.71 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL2323672 | 0.70 | LMNA (0.35) | MAPK1ATMALDH1A1LMNAPKM | |
| SCHEMBL10564664 | 0.70 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL28988152 | 0.70 | ERN1 (0.33) | PKM | |
| SCHEMBL28693016 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111712492-B | Cyclotriazoles as LPA antagonists | 百时美施贵宝公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-3728224-B1 | CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11319315-B2 | Cyclohexyl acid triazole azoles as LPA antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210163470-A1 | CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| CN-111712492-A | Cyclohexaneacetic acid triazolazoles as LPA antagonists | 百时美施贵宝公司 | 2020-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319315-B2 | Cyclohexyl acid triazole azoles as LPA antagonists | LPAR3, LPAR1, LPAR2 | TOP2A 2949/4885MAPK1 341/4885ATM 2913/4885 |
| US-20210163470-A1 | CYCLOHEXYL ACID TRIAZOLE AZOLES AS LPA ANTAGONISTS | LPAR3, LPAR1, LPAR2 | TOP2A 2949/4885MAPK1 341/4885ATM 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.